EMA Overhauls Guidance On Risk Minimization Activities

 
• By Vibha Sharma
  
Generate a summary of this article
Listen to this article
Beta

Drug companies may have to adjust their benefit-risk management strategies to ensure compliance with the European Medicines Agency’s newly revised guidance on how to develop and evaluate risk minimization measures.

Medicine, help and pharmacist advice with side effects at health store counter for customer service. Pharmaceutical advice and opinion of worker helping girl with medication information at pharmacy.
Educational Materials, Package Leaflets And Restricted Pack Sizes Are All Types Of Risk Minimization Activities • Source: Shutterstock

The European Medicines Agency has published keenly-awaited revised EU guidance on what measures drug companies can employ to prevent or minimize the risks associated with their products, along with a revised addendum on how to gauge the effectiveness of such measures.

Key Takeaways

  • The European Medicines Agency has finalized long-awaited changes to its good pharmacovigilance guideline Module XVI on risk minimization measures (RMM) and a related addendum.

The revisions were made to the guideline on risk minimization measures (RMMs) – ie, Module XVI of the EMA’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.